Thomas Mesnard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thomas Mesnard has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Sobocinski
Department of Vascular Surgery, Aortic Centre, CHRU Lille, Lille, France
10 shared publications - Gustavo S. Oderich
Department of Cardiothoracic & Vascular Surgery, Advanced Aortic Research Program at the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX
9 shared publications Jonathan Sobocinski
Service de chirurgie vasculaire, Centre de l’Aorte, CHU Lille, Université de Lille, France
8 shared publicationsYing Huang
Division of Vascular Surgery and Endovascular Therapy, Center for Aortic Surgery, Baylor College of Medicine, Houston, TX
8 shared publicationsAndrea Vacirca
Department of Cardiothoracic and Vascular Surgery, Advanced Aortic Research Program at the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX; Vascular Surgery, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
6 shared publications- Lucas Ruiter Kanamori
Advanced Endovascular Aortic Research Program, Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX
6 shared publications
Latest Publications
- 12 August 2026
- Published by SAGE Publications in Journal of Endovascular Therapy
Multicentre Cohort of Acute Type B Intramural Haematoma: Outcomes and Predictors of Aortic Complications
Purpose: To analyse predictors of aortic complications (ACs) and outcomes of patients admitted for acute type B intramural haematoma (IMH-B). Methods: A retrospective analysis of data of patients diagnosed with acute IMH-B from 7 French tertiary centres between December 2003 and December 2019 was conducted. Baseline demographics, initial anatomical features, indication and treatment modality during the acute phase including either thoracic endovascular aortic repair (TEVAR) and optimal medical therapy (OMT) or OMT alone were recorded. The primary endpoint was the occurrence of any AC during follow-up, defined as a composite criterion including aortic rupture, ulcer-like projection, aortic dissection or aneurysmal degeneration. Secondary endpoints included freedom from all-cause mortality and from aortic-related intervention. Results: Eighty-one patients (52% male, median age 72 [62-77]) were included. Medical therapy initiated during the acute phase included more than 2 antihypertensive drugs in 39 (48%) patients. Nine patients (11%) underwent urgent (P = .025) and the maximum aortic true lumen diameter at admission (HR [per 1 mm increment] = 1.07 [1.02-1.13]; P = .009) were predictors of AC. Conclusion: After acute type B IMH, ACs are most prevalent within the first year, mandating close early clinical and imaging follow-up. Larger presenting aortic lumen maximum diameter is associated with increased likelihood of AC. Clinical Impact: Intramural haematoma (IMH) is a rare condition. While invasive treatment with thoracic stent-grafts has become the standard of care for complicated cases, treatment indications during the acute phase remain a matter of debate, and the natural history of the condition is not fully understood. This study, which included 81 patients with type B IMH (IMH-B), suggests that a presenting aortic lumen diameter greater than 27 mm and a history of aortic surgery are predictive for the risk of ACs after acute IMH-B, mandating closer imaging and clinical monitoring.
- 12 August 2026
- Published by SAGE Publications in Journal of Endovascular Therapy
Multicentre Cohort of Acute Type B Intramural Haematoma: Outcomes and Predictors of Aortic Complications
Purpose: To analyse predictors of aortic complications (ACs) and outcomes of patients admitted for acute type B intramural haematoma (IMH-B). Methods: A retrospective analysis of data of patients diagnosed with acute IMH-B from 7 French tertiary centres between December 2003 and December 2019 was conducted. Baseline demographics, initial anatomical features, indication and treatment modality during the acute phase including either thoracic endovascular aortic repair (TEVAR) and optimal medical therapy (OMT) or OMT alone were recorded. The primary endpoint was the occurrence of any AC during follow-up, defined as a composite criterion including aortic rupture, ulcer-like projection, aortic dissection or aneurysmal degeneration. Secondary endpoints included freedom from all-cause mortality and from aortic-related intervention. Results: Eighty-one patients (52% male, median age 72 [62-77]) were included. Medical therapy initiated during the acute phase included more than 2 antihypertensive drugs in 39 (48%) patients. Nine patients (11%) underwent urgent (P = .025) and the maximum aortic true lumen diameter at admission (HR [per 1 mm increment] = 1.07 [1.02-1.13]; P = .009) were predictors of AC. Conclusion: After acute type B IMH, ACs are most prevalent within the first year, mandating close early clinical and imaging follow-up. Larger presenting aortic lumen maximum diameter is associated with increased likelihood of AC. Clinical Impact: Intramural haematoma (IMH) is a rare condition. While invasive treatment with thoracic stent-grafts has become the standard of care for complicated cases, treatment indications during the acute phase remain a matter of debate, and the natural history of the condition is not fully understood. This study, which included 81 patients with type B IMH (IMH-B), suggests that a presenting aortic lumen diameter greater than 27 mm and a history of aortic surgery are predictive for the risk of ACs after acute IMH-B, mandating closer imaging and clinical monitoring.
- 9 July 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 72 (5) , 858-859
Four Year Updated Results with the BeGraft Stent Graft as Bridging Stents in Fenestrated Endovascular Aortic Repair
- 9 July 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 72 (5) , 858-859
Four Year Updated Results with the BeGraft Stent Graft as Bridging Stents in Fenestrated Endovascular Aortic Repair
- 1 March 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (4) , 1120-1128
Trends in Abdominal Aortic Aneurysm Management in France Between 2012 and 2021 From the French Nationwide Database: Treatment Modalities and Outcomes
Background: This study aimed to analyze recent trends of surgical management and early outcomes in the treatment of abdominal aortic aneurysm (AAA) from the French national Health Data System (SNDS). Methods: This study was a retrospective multicenter cohort study based on a national medico‐economic database. All ruptured (rAAA) or intact AAA (iAAA) treated between 2012 and 2021 related to a primary procedure code for endovascular aneurysm repair (EVAR) or open aortic surgery (OAR) extracted from the SNDS were included. The modified Elixhauser score was used for grading patient's comorbidities. The primary endpoint was to describe the evolution of practices in France regarding the management of AAA and associated inhospital outcomes. Secondary endpoints included identifying predictors of inhospital mortality, assessing center volume, and analyzing overall survival during follow‐up. Results: Overall, 70,088 AAAs were included, comprising 5648 rAAA, 1579 (28%) treated with EVAR and 4069 (72%) with OAR, and 64,440 iAAAs, of which 41,916 (65%) underwent EVAR and 22,524 (35%) OAR. Over the study period, the proportion of EVAR increased significantly, whereas 30‐day mortality remained stable, except for rAAA treated with EVAR, where it varied over time. EVAR was associated with lower 30‐day mortality compared to OAR for both iAAAs (1.3% vs. 4.1%; p < 0.001) and rAAA (18.7% vs. 35.5%; p < 0.001). For both iAAA and rAAA, significant predictors of inhospital mortality included a higher Elixhauser comorbidity score, and age ≥ 80 years, female sex. Also, OAR was independently associated with higher inhospital mortality (adjusted OR 1.96 for iAAA and 2.22 for rAAA). A graphical association was observed between higher center volume and lower inhospital mortality. The estimated 8‐year survival for iAAA was 46% after EVAR and 56% after OAR (log rank p = 0.002). Conclusions: The proportion of iAAA and rAAA treated with EVAR increased throughout the study period. Increased Elixhauser score, age over 80 years, and female sex are associated with increased postoperative mortality. Higher volume centers have improved postoperative mortality rates.
- 1 March 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (4) , 1120-1128
Trends in Abdominal Aortic Aneurysm Management in France Between 2012 and 2021 From the French Nationwide Database: Treatment Modalities and Outcomes
Background: This study aimed to analyze recent trends of surgical management and early outcomes in the treatment of abdominal aortic aneurysm (AAA) from the French national Health Data System (SNDS). Methods: This study was a retrospective multicenter cohort study based on a national medico‐economic database. All ruptured (rAAA) or intact AAA (iAAA) treated between 2012 and 2021 related to a primary procedure code for endovascular aneurysm repair (EVAR) or open aortic surgery (OAR) extracted from the SNDS were included. The modified Elixhauser score was used for grading patient's comorbidities. The primary endpoint was to describe the evolution of practices in France regarding the management of AAA and associated inhospital outcomes. Secondary endpoints included identifying predictors of inhospital mortality, assessing center volume, and analyzing overall survival during follow‐up. Results: Overall, 70,088 AAAs were included, comprising 5648 rAAA, 1579 (28%) treated with EVAR and 4069 (72%) with OAR, and 64,440 iAAAs, of which 41,916 (65%) underwent EVAR and 22,524 (35%) OAR. Over the study period, the proportion of EVAR increased significantly, whereas 30‐day mortality remained stable, except for rAAA treated with EVAR, where it varied over time. EVAR was associated with lower 30‐day mortality compared to OAR for both iAAAs (1.3% vs. 4.1%; p < 0.001) and rAAA (18.7% vs. 35.5%; p < 0.001). For both iAAA and rAAA, significant predictors of inhospital mortality included a higher Elixhauser comorbidity score, and age ≥ 80 years, female sex. Also, OAR was independently associated with higher inhospital mortality (adjusted OR 1.96 for iAAA and 2.22 for rAAA). A graphical association was observed between higher center volume and lower inhospital mortality. The estimated 8‐year survival for iAAA was 46% after EVAR and 56% after OAR (log rank p = 0.002). Conclusions: The proportion of iAAA and rAAA treated with EVAR increased throughout the study period. Increased Elixhauser score, age over 80 years, and female sex are associated with increased postoperative mortality. Higher volume centers have improved postoperative mortality rates.
- 13 December 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (5) , 887-888
Early Clinical Experience with Intra-operative Cone Beam Computerised Tomography Using a Mobile C Arm System for Aorto-Iliac Endovascular Procedures
- 13 December 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (5) , 887-888
Early Clinical Experience with Intra-operative Cone Beam Computerised Tomography Using a Mobile C Arm System for Aorto-Iliac Endovascular Procedures
- Open Access
- 5 November 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (6) , 1026-1033
Fenestrated Endovascular Aortic Repair and Open Surgical Repair in Patients with Type Ia Endoleak after Endovascular Aneurysm Repair: a French Multicentre Cohort Study with Propensity Score Matching
- 5 November 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (6) , 1026-1033
Open AccessFenestrated Endovascular Aortic Repair and Open Surgical Repair in Patients with Type Ia Endoleak after Endovascular Aneurysm Repair: a French Multicentre Cohort Study with Propensity Score Matching
- 16 July 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 70 (1) , e13-e14
Predictors of failure to rescue after fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms
- 16 July 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 70 (1) , e13-e14
Predictors of failure to rescue after fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms
- 5 March 2025
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 82 (1) , 32-42.e3
Predictors of failure to rescue after fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms
- 5 March 2025
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 82 (1) , 32-42.e3
Predictors of failure to rescue after fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms
- 19 February 2025
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 33 (4) , 1922-1930
Type IA Endoleak Correction With Fenestrated Devices After EVAR: Outcomes and Predictors of Secondary Failure
Purpose: The aim of this study was to review the results of fenestrated stent-graft (Fenestrated Endovascular Aortic Repair [FEVAR]) implantation to treat patients with type IA endoleaks after prior infrarenal endovascular aortic repair (EVAR). Methods: A retrospective single-center analysis of prospectively collected data was conducted, including consecutive patients who underwent FEVAR to correct a type IA endoleak between November 2009 and April 2021. All devices were manufactured by Cook Medical (INC, Bloomington, Indiana). Demographic details, anatomical features, fenestrated stent-graft configuration, technical success, and major adverse events (MAEs) were recorded according to current SVS standards. The primary endpoint was freedom-from-significant aneurysm sac expansion (≥5 mm) and survival according to the Kaplan-Meier analysis. Secondary endpoints included 30-day outcomes, freedom-from-all-cause mortality, and aortic-related secondary interventions. Multivariate Cox regression was performed to identify factors associated with the study endpoints. Results: Overall, 47 patients (89% male, median age 80) were included. Median time from initial EVAR was 60 months [41-72]. Median pre-FEVAR maximal aneurysm diameter was 68mm [62-79]. Median fluoroscopy time and dose area product were, respectively, 49 min [36-63] and 66 Gy.cm2 [38-101]. Technical success rate was 96% with no 30-day deaths reported. Two (4.3%) renal MAE occurred. Median follow-up was 22 months [12-36]. Two-year freedom-from-aneurysm sac expansion and aortic-related secondary intervention were 80% [66-96] and 69% [55-87], respectively. From the multivariate analysis, the configuration of the fenestrated device was not predictive of aneurysm sac expansion, whereas only the preoperative aneurysm maximal diameter was an independent predictor (hazard ratio [HR] [per 1 mm increment]=1.05 [1.01-1.10]; p=0.016) and was associated with a higher risk of aortic-related secondary intervention (HR [per 1 mm increment]=1.07 [1.02-1.12]; p=0.006). Other predictors of aortic-related secondary intervention were pre-existing type IB or III endoleak (HR=7.89 [1.39-44.8]; p=0.020) and aortic degeneration above the primary EVAR (HR=16.6 [1.88-147], p=0.011). Conclusion: Late type IA endoleak after EVAR can be treated safely with a fenestrated stent-graft; preoperative maximum aneurysm diameter is associated with an increased risk of later aneurysm sac growth. Close follow-up is mandatory in this subgroup of patients given the high reintervention rate. Clinical Impact: Type IA endoleak following endovascular aneurysm repair (EVAR) can be treated using a fenestrated stent-graft (FEVAR). Treatment options include the addition of a fenestrated cuff alone or complete relining of the previous graft with either a 3-component device or a unibody bifurcated FEVAR. Regardless of the device configuration the treatment appears to be safe but remains associated with high rates of reintervention and aneurysm growth. Although no significant differences have been observed in long-term outcomes, a complete relining with a bifurcated FEVAR may be preferred as a first-line approach, as it offers the advantage of addressing occult associated Type III endoleaks and reducing the risk of component disconnection.
- 19 February 2025
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 33 (4) , 1922-1930
Type IA Endoleak Correction With Fenestrated Devices After EVAR: Outcomes and Predictors of Secondary Failure
Purpose: The aim of this study was to review the results of fenestrated stent-graft (Fenestrated Endovascular Aortic Repair [FEVAR]) implantation to treat patients with type IA endoleaks after prior infrarenal endovascular aortic repair (EVAR). Methods: A retrospective single-center analysis of prospectively collected data was conducted, including consecutive patients who underwent FEVAR to correct a type IA endoleak between November 2009 and April 2021. All devices were manufactured by Cook Medical (INC, Bloomington, Indiana). Demographic details, anatomical features, fenestrated stent-graft configuration, technical success, and major adverse events (MAEs) were recorded according to current SVS standards. The primary endpoint was freedom-from-significant aneurysm sac expansion (≥5 mm) and survival according to the Kaplan-Meier analysis. Secondary endpoints included 30-day outcomes, freedom-from-all-cause mortality, and aortic-related secondary interventions. Multivariate Cox regression was performed to identify factors associated with the study endpoints. Results: Overall, 47 patients (89% male, median age 80) were included. Median time from initial EVAR was 60 months [41-72]. Median pre-FEVAR maximal aneurysm diameter was 68mm [62-79]. Median fluoroscopy time and dose area product were, respectively, 49 min [36-63] and 66 Gy.cm2 [38-101]. Technical success rate was 96% with no 30-day deaths reported. Two (4.3%) renal MAE occurred. Median follow-up was 22 months [12-36]. Two-year freedom-from-aneurysm sac expansion and aortic-related secondary intervention were 80% [66-96] and 69% [55-87], respectively. From the multivariate analysis, the configuration of the fenestrated device was not predictive of aneurysm sac expansion, whereas only the preoperative aneurysm maximal diameter was an independent predictor (hazard ratio [HR] [per 1 mm increment]=1.05 [1.01-1.10]; p=0.016) and was associated with a higher risk of aortic-related secondary intervention (HR [per 1 mm increment]=1.07 [1.02-1.12]; p=0.006). Other predictors of aortic-related secondary intervention were pre-existing type IB or III endoleak (HR=7.89 [1.39-44.8]; p=0.020) and aortic degeneration above the primary EVAR (HR=16.6 [1.88-147], p=0.011). Conclusion: Late type IA endoleak after EVAR can be treated safely with a fenestrated stent-graft; preoperative maximum aneurysm diameter is associated with an increased risk of later aneurysm sac growth. Close follow-up is mandatory in this subgroup of patients given the high reintervention rate. Clinical Impact: Type IA endoleak following endovascular aneurysm repair (EVAR) can be treated using a fenestrated stent-graft (FEVAR). Treatment options include the addition of a fenestrated cuff alone or complete relining of the previous graft with either a 3-component device or a unibody bifurcated FEVAR. Regardless of the device configuration the treatment appears to be safe but remains associated with high rates of reintervention and aneurysm growth. Although no significant differences have been observed in long-term outcomes, a complete relining with a bifurcated FEVAR may be preferred as a first-line approach, as it offers the advantage of addressing occult associated Type III endoleaks and reducing the risk of component disconnection.